Advertisement
New Zealand markets closed
  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     
  • NZD/USD

    0.5892
    -0.0013 (-0.22%)
     
  • NZD/EUR

    0.5523
    -0.0022 (-0.39%)
     
  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     
  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     
  • OIL

    83.24
    +0.51 (+0.62%)
     
  • GOLD

    2,406.70
    +8.70 (+0.36%)
     
  • NASDAQ

    17,037.65
    -356.67 (-2.05%)
     
  • FTSE

    7,895.85
    +18.80 (+0.24%)
     
  • Dow Jones

    37,986.40
    +211.02 (+0.56%)
     
  • DAX

    17,737.36
    -100.04 (-0.56%)
     
  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • NZD/JPY

    91.0710
    -0.1830 (-0.20%)
     

Wall Street Analysts Are Mostly Positive on Jazz Pharmaceuticals

Wall Street Analysts Are Mostly Positive on Jazz Pharmaceuticals

In August 2018, Jazz Pharmaceuticals (JAZZ) and the University of Texas MD Anderson Cancer Center entered a five-year collaboration agreement to investigate therapies for the treatment of multiple hematologic malignancies such as AML (acute myeloid leukemia) and myelodysplastic syndrome.